Compare · GMTX vs JNJ
GMTX vs JNJ
Side-by-side comparison of Gemini Therapeutics Inc. (GMTX) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GMTX and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $549.25B, about 7117.3x GMTX ($77.2M).
- JNJ has hit the wire 12 times in the past 4 weeks while GMTX has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 7 for GMTX).
- Company
- Gemini Therapeutics Inc.
- Johnson & Johnson
- Price
- $13.50+938.46%
- $228.27+2.08%
- Market cap
- $77.2M
- $549.25B
- 1M return
- -
- +1.20%
- 1Y return
- -
- +48.62%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 12
- Recent ratings
- 7
- 25
Gemini Therapeutics Inc.
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest GMTX
- Franchi Jean M. was granted 36,666 shares (SEC Form 4)
- SEC Form 3 filed by new insider Franchi Jean M.
- SEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)
- SEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)
- SEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)
- Gemini Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- SEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)
- SEC Form SC 13D/A filed by Gemini Therapeutics Inc. (Amendment)
- Bitterman Kevin sold $6,934,125 worth of shares (102,500 units at $67.65) (SEC Form 4)
- Atlas Venture Fund X, L.P. sold $10,147,500 worth of shares (150,000 units at $67.65) (SEC Form 4)
Latest JNJ
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
- Johnson & Johnson upgraded by Leerink Partners with a new price target